Acenxion Biosystems announce a close on a common stock Angel round

[Kansas City, KS]  Acenxion Biosystems is pleased to announce a close on a common stock Angel round that resulted in just under $1M of unrestricted funding. Board member Brian Struchtemeyer said, “We’re extremely happy about this round as it was overwhelmingly filled by existing investors. That made my job in coordinating this round extremely easy. The level of support our team of scientists, engineers, and also investors continue to demonstrate is astonishing and reinforces the fantastic progress the company has been making. This funding will facilitate the completion of several key milestones and we’re extremely excited to reveal our prototype in the very near future.”

Specific terms of the round were not released.

Acenxion Biosystems (ACXBIO) is a privately funded company developing automated systems for bacteria detection in blood cultures and phenotypic antimicrobial susceptibility testing (AST). Seamlessly fitting into current clinical workflows, Acenxion’s scalable AST system reduces the time required for phenotypic testing to just 4-6 hours, allowing clinicians rapid use of a precise, targeted treatment. Acenxion’s technology improves patient outcomes, reduces healthcare costs, and reduces the spread of antibiotic resistance extending the service life of antibiotics.